Benefits
Better absorbed than standard berberine (five person pilot)
In a randomized crossover pilot trial in five healthy young men, 100 mg of dihydroberberine produced roughly 5 times the plasma berberine exposure and about 3 times the peak level of 500 mg of standard berberine over a two hour window. Two things to keep in mind: the doses compared were not equal, and this was an absorption pilot in five people, not an efficacy trial. Blood glucose and insulin did not change significantly during the measurement period, and digestive side effects were not compared between the two forms.
Blood sugar and insulin regulation
Berberine, the compound dihydroberberine turns back into in the body, activates the cellular energy sensor AMPK in laboratory work. A meta-analysis of randomized trials found that plain berberine lowered fasting blood glucose and HbA1c in people already diagnosed with type 2 diabetes and under medical care. That research used standard berberine in patients, not the branded DHB form and not healthy people. None of the studies cited on this page measured GLP-1 or any other incretin hormone, and none compared this ingredient with prescription metformin or GLP-1 medications.
Cholesterol and triglycerides (studied as plain berberine)
A meta-analysis of randomized trials found that plain berberine improved total cholesterol, LDL cholesterol and triglycerides. That evidence is for standard berberine, not the branded DHB form. None of the studies cited here measured body weight, body fat or muscle glycogen, so there is no cited human data showing that this ingredient changes where carbohydrate is stored or improves body composition.
Gut microbiome support
A mechanistic study in people and animals found that plain berberine's cholesterol lowering effect depends partly on changes in gut bacteria. That work used berberine rather than dihydroberberine, and it was designed to explain how cholesterol lowering happens, not to show that this ingredient improves gut health on its own.
Mechanism of action
AMPK activation pathway
In laboratory research, berberine inhibits mitochondrial Complex I, which briefly raises the AMP to ATP ratio and switches on AMPK, a cellular energy sensor. In cell and animal studies, activated AMPK is linked to glucose uptake, fat burning and lower glucose output from the liver. This is a proposed explanation, not something measured in the human studies cited on this page.
Enhanced intestinal absorption
Unlike berberine (which is poorly absorbed and irritates intestinal tissue at high doses), dihydroberberine is absorbed via passive diffusion in the upper GI tract, then converted back to berberine in the body. The five person pilot measured berberine in the blood, not in tissues, so higher tissue levels are a proposed explanation rather than a measured result.
GLP-1: a marketing claim that was never measured
You will often see marketing claiming this ingredient raises GLP-1, the gut hormone that prescription drugs such as semaglutide and tirzepatide act on. None of the published studies cited on this page measured GLP-1 or any other incretin hormone, and there is no peer reviewed trial behind the 95% figure. Treat it as an untested marketing claim rather than a demonstrated effect, and do not treat this ingredient as a substitute for a prescribed medication.
Clinical trials
Randomized, controlled, crossover pilot trial comparing absorption of berberine and dihydroberberine in healthy men. Outcomes measured: plasma berberine AUC and peak level, plus blood glucose and insulin. Published in Nutrients, 2021 (PMID 35010998).
Five healthy young men (average age 26).
In five men, 100 mg of dihydroberberine produced roughly 5 times the plasma berberine AUC and about 3 times the peak level of 500 mg of standard berberine. Blood glucose and insulin did not change significantly during the two hour measurement window. Critical caveat: pilot pharmacokinetic study, not efficacy. The 5× bioavailability claim is supported, but does not directly prove that 100 mg DHB equals 500 mg berberine for clinical outcomes — showing a real health benefit would require head to head trials measuring actual outcomes, and those have not been published.
This entry describes the same published pilot study listed above (Nutrients, 2021, PMID 35010998), which measured absorption, blood glucose and insulin. It did not measure GLP-1, and we found no peer reviewed trial testing GlucoVantage on GLP-1 secretion.
5 healthy young men (mean age 26). Randomized, double-blind, crossover pilot trial; 4 doses each of placebo, 500 mg berberine, 100 mg DHB (GlucoVantage®), or 200 mg DHB.
100 mg DHB produced ~5× higher plasma berberine AUC and ~3× higher Cmax vs 500 mg standard berberine over 2-hour window. No significant glucose or insulin changes during the short PK period. It showed that a lower dose of DHB delivered comparable or higher plasma berberine. Digestive side effects were not an outcome of this study, so the claim of less stomach upset was not tested here. With five participants and a single short session, this is a pilot, not proof of any health effect.